The content on this page is designed for Europe. Check courses designed for Canada (EN)

This course has expired. View available courses.

Endocrinology

Advancement of Antihyperglycemic Therapy – The Management of Type 2 Diabetes is Evolving with New Data (Unaccredited)

Type 2 diabetes is typically a progressive condition where therapy advancement will normally be required for the patient to reaching glycemic targets. Although all guidelines recommend therapy advancement to reach glycemic targets, there is commonly inertia to add additional agents. Some of the reason for this inertia is likely due to the significant advances in therapy recommendations for people with type 2 diabetes. This allows for treatment that focuses beyond glycemic control, and the selection of agents that reduce the burden of diabetic complications. In this webinar, we will hear from international experts providing guidance on the individualization of therapy in patients with type 2 diabetes to improve glycemic control and reduce complication risk.


This program has received an unrestricted educational grant or in-kind support from Novo Nordisk A/S.

DURATION

1 hr

PROFESSION

Physician, Specialist

# OF CREDITS

0

ACCREDITATION

Unaccredited

EXPIRY DATE

2022-11-15

Type 2 diabetes is typically a progressive condition where therapy advancement will normally be required for the patient to reaching glycemic targets. Although all guidelines recommend therapy advancement to reach glycemic targets, there is commonly inertia to add additional agents. Some of the reason for this inertia is likely due to the significant advances in therapy recommendations for people with type 2 diabetes. This allows for treatment that focuses beyond glycemic control, and the selection of agents that reduce the burden of diabetic complications. In this webinar, we will hear from international experts providing guidance on the individualization of therapy in patients with type 2 diabetes to improve glycemic control and reduce complication risk.


This program has received an unrestricted educational grant or in-kind support from Novo Nordisk A/S.

Faculty

Peter Lin, MD, CCFP (Moderator)
David Strain, MD, FRCP, MBChB
Dipesh Patel, PhD, FRCP
Kim Connelly, MBBS PhD FSCMR FCCS
Roopa Mehta, MBBS, MRCP
Rene Wong, MD, MEd, PhD, FRCPC
Dirk Pilat, FRCGP, PgDipGP, BSc
James Kim, MBBCh, PgDip
Maureen Clement, MD, CCFP

Cost of course:  
Free
# of credits: 0
Duration: 1 hr

FAQs & HELP

MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.

All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.

The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

No, registration with MDBriefCase is free!

To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.

If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.

Please note: if you submitted multiple password resets, only the link on the most recent email is valid.

You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.

Advancement of Antihyperglycemic Therapy – The Management of Type 2 Diabetes is Evolving with New Data (Unaccredited)

1 hr

Duration

Physician, Specialist

Profession

0

# of credits

Learning Objectives

ACF Learning Objectives

Unaccredited

ACCREDITATION

Endocrinology

Learning Category

Diabetes

Topic

0

Price

2022-11-15

Expiry Date

EU

Region/Language

Course Description

Type 2 diabetes is typically a progressive condition where therapy advancement will normally be required for the patient to reaching glycemic targets. Although all guidelines recommend therapy advancement to reach glycemic targets, there is commonly inertia to add additional agents. Some of the reason for this inertia is likely due to the significant advances in therapy recommendations for people with type 2 diabetes. This allows for treatment that focuses beyond glycemic control, and the selection of agents that reduce the burden of diabetic complications. In this webinar, we will hear from international experts providing guidance on the individualization of therapy in patients with type 2 diabetes to improve glycemic control and reduce complication risk.


This program has received an unrestricted educational grant or in-kind support from Novo Nordisk A/S.

Faculty

Peter Lin, MD, CCFP (Moderator)
David Strain, MD, FRCP, MBChB
Dipesh Patel, PhD, FRCP
Kim Connelly, MBBS PhD FSCMR FCCS
Roopa Mehta, MBBS, MRCP
Rene Wong, MD, MEd, PhD, FRCPC
Dirk Pilat, FRCGP, PgDipGP, BSc
James Kim, MBBCh, PgDip
Maureen Clement, MD, CCFP

Accreditation

Unaccredited